Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 3/20 | 0.57 |
| ▸ | RXRA | P19793 | 1/20 | 0.52 |
| ▸ | RXRB | P28702 | 1/20 | 0.52 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.44 |
| ▸ | TTR | P02766 | 1/20 | 0.44 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.43 |
| ▸ | KMO | O15229 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29386074 | 1.00 | ERN1 (0.57) | ERN1RXRARXRBCRHBPCRHR2 | |
| SCHEMBL408308 | 0.86 | ERN1 (0.59) | ERN1RXRARXRBCRHBPCRHR2 | |
| SCHEMBL2404933 | 0.86 | TTR (0.48) | ERN1CRHBPCRHR2CASP6TTR | |
| SCHEMBL31415060 | 0.86 | ERN1 (0.59) | ERN1RXRARXRBCRHBPCRHR2 | |
| SCHEMBL4348393 | 0.85 | ERN1 (0.54) | ERN1RXRARXRBCRHBPCRHR2 | |
| SCHEMBL3360547 | 0.84 | ERN1 (0.57) | ERN1CRHBPCRHR2TP53CASP6 | |
| SCHEMBL3360693 | 0.84 | ERN1 (0.57) | ERN1CRHBPCRHR2TP53CASP6 | |
| Bromide SCHEMBL3516464 | 0.83 | ERN1 (0.56) | ERN1CRHBPCRHR2TP53CASP6 | |
| SCHEMBL14086411 | 0.83 | TPMT (0.49) | ERN1RXRARXRBTP53CASP6 | |
| SCHEMBL2407536 | 0.82 | HCAR2 (0.46) | ERN1CRHBPCRHR2CASP6TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040019190-A1 | Thrombopoietin mimetics | NOVARTIS AG (CH) | 2004-01-29 | — | — | US | claimed |
| US-12435042-B2 | Process for the preparation of key intermediates for the synthesis of Eltrombopag or salt thereof | F.I.S.—Fabbrica Italiana Sintetici S.p.A. (IT) | 2025-10-07 | — | — | US | disclosed |
| US-20220298116-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF ELTROMBOPAG OR SALT THEREOF | F.l.S. - FABBRICA ITALIANA SINTETICI S.P.A (IT) | 2022-09-22 | — | — | US | disclosed |
| EP-3994126-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF ELTROMBOPAG OR SALT THEREOF | F.I.S.- Fabbrica Italiana Sintetici S.p.A. (IT) | 2022-05-11 | — | — | EP | disclosed |
| WO-2021001044-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF ELTROMBOPAG OR SALT THEREOF | F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2021-01-07 | — | — | WO | disclosed |
| US-20150093356-A1 | THROMBOPOIETIN MIMETICS | GLAXOSMITHKLINE LLC | 2015-04-02 | — | — | US | disclosed |
| WO-2013049605-A1 | PROCESSES FOR THE PREPARATION OF AN INTERMEDIATE IN THE SYNTHESIS OF ELTROMBOPAG | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013049605-A1 | PROCESSES FOR THE PREPARATION OF AN INTERMEDIATE IN THE SYNTHESIS OF ELTROMBOPAG | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2013-04-04 | — | — | WO | disclosed |
| US-20130078213-A1 | THROMBOPOIETIN MIMETICS | GLAXOSMITHKLINE LLC | 2013-03-28 | — | — | US | disclosed |
| US-20110212054-A1 | THROMBOPOIETIN MIMETICS | GLAXOSMITHKLINE LLC. | 2011-09-01 | — | — | US | disclosed |
| EP-1889838-A1 | Thrombopoietin mimetics | SmithKline Beecham Corporation (US) | 2008-02-20 | — | — | EP | disclosed |
| US-7332481-B2 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-19 | — | — | US | disclosed |
| EP-1864981-A1 | Thrombopoietin mimetics | SmithKline Beecham Corporation (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20070179192-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION AND GLAXO GROUP LIMITED | 2007-08-02 | — | — | US | disclosed |
| US-20070129338-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION | 2007-06-07 | — | — | US | disclosed |
| US-7160870-B2 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| US-20040019190-A1 | Thrombopoietin mimetics | NOVARTIS AG (CH) | 2004-01-29 | — | — | US | disclosed |
| EP-1294378-A4 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORP (US) | 2004-01-28 | — | — | EP | disclosed |
| EP-1294378-A2 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-03-26 | — | — | EP | disclosed |
| WO-2001089457-A2 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129338-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | ERN1 4239/4885RXRA 4434/4885RXRB 2974/4885 |
| US-20070179192-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | ERN1 4239/4885RXRA 4434/4885RXRB 2974/4885 |
| US-20150093356-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | ERN1 4239/4885RXRA 4434/4885RXRB 2974/4885 |
| US-12435042-B2 | Process for the preparation of key intermediates for the synthesis of Eltrombopag or salt thereof | HABP2, F5, THPO | ERN1 2591/4885RXRA 3185/4885RXRB 3068/4885 |
| US-20110212054-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | ERN1 4239/4885RXRA 4434/4885RXRB 2974/4885 |
| US-20130078213-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | ERN1 4239/4885RXRA 4434/4885RXRB 2974/4885 |
| US-20220298116-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF ELTROMBOPAG OR SALT THEREOF | HABP2, F5, THPO | ERN1 2591/4885RXRA 3185/4885RXRB 3068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.